Researchers found that if people were given a half dose followed by a full dose, rather than two full doses, protection rose to about 90 percent.
Pharmaceutical company AstraZeneca said Monday late-stage trials of its Covid-19 vaccine have shown it to be “highly effective” in preventing disease.
“We’ve found that one of our dosing regimens possibly around 90% effective and if this dosing system is utilized, more individuals could be vaccinated with planned vaccine supply,” said Professor Andrew Pollard, boss examiner of the Oxford antibody preliminary.
Analysis of data from a phase 3 trial showed that the vaccine, developed in conjunction with the U.K.’s University of Oxford, was 90 percent effective at stopping the disease when half a dose was administered followed by a full dose. In another dosing regiment, when two full doses were administered, the vaccine was 62 percent effective, researchers said, resulting in combined average efficacy of 70 percent.
More analysis is expected to determine how long the protection rendered by the vaccine could last.
Related Article: Pfizer Says Coronavirus Vaccine It’s ‘94% Effective In Over 65s’
The results of AstraZeneca’s vaccine trials are the third promising breakthrough in the battle against the COVID pandemic that has killed nearly 1.4 million individuals and annoyed the worldwide economy.
Earlier this month, Pfizer and Moderna reported preliminary results from late-stage trials, showing that their vaccine candidates were just about 95% successful.
The creators of the AstraZeneca vaccine, which uses a weakened version of a common cold virus, said it could be administered in existing healthcare settings, like medical clinics and local pharmacies, and stored at a “fridge temperature” of 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit) for at least six months, making its distribution easier.
There were no hospitalized or severe cases in any individual who got the vaccine, scientists said.
English Prime Minister Boris Johnson welcomed the news however warned that more research was required before a vaccine was distributed widely.
“Incredibly exciting news the Oxford vaccine has proved so effective in trials,” he said in a tweet. “There are still further safety checks ahead, but these are fantastic results.”
Researchers said 131 Covid-19 cases were detected in over 24,000 volunteers from diverse racial and geographical groups in clinical trials in the U.K., Brazil, and South Africa. Further trials are also being conducted in the U.S., Kenya, Russia, Japan, and India.
The vaccine efficacy information will presently be submitted to regulators over the world, the organization said, including in the U.K., Europe, and Brazil, for review and approval. It will also seek an emergency use approval from the World Health Organization for a quickened pathway to vaccine availability in low-pay nations.
This news is picked up from NBC News